A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors

A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors

Here, the authors provide a panel of medium-throughput assays to test potential drug candidates against different life cycle stages of Cryptosporidium with the goal to support a drug development pipeline that contains compounds with diverse molecular mechanisms of action.

Bibliographic Details
Main Authors: Rajiv S. Jumani, Muhammad M. Hasan, Erin E. Stebbins, Liam Donnelly, Peter Miller, Connor Klopfer, Kovi Bessoff, Jose E. Teixeira, Melissa S. Love, Case W. McNamara, Christopher D. Huston
Format: Article
Language:English
Published: Nature Publishing Group 2019-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-09880-w

Internet

https://doi.org/10.1038/s41467-019-09880-w

Similar Items